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ABSTRACT: Following balloon injury, smooth muscle cells
(SMCs) serve as targets for many of the pro-inflammatory and
pro-fibrotic factors, including platelet-derived growth factor
(PDGF) and interferon-γ (IFN-γ) released from activated
inflammatory cells and platelets. Previously, our lab designed a
mimic of the proteoglycan decorin, termed DS-SILY20, that
suppressed vascular SMC proliferation, migration, and protein
synthesis in vitro, and injured vessels treated with DS-SILY20
demonstrated reduced hyperplasia in vivo. Here we characterize
the effects of DS-SILY20 on modulating PDGF and IFN-γ
stimulation in both proliferative and quiescent human SMCs to
further evaluate the potential impact of DS-SILY20-SMC interaction on restenosis. Nanomolar dissociation constants were
observed between DS-SILY20 and both PDGF and IFN-γ. PDGF significantly increased migration, proliferation, and protein and
cytokine expression, as well as increased ERK-1/2 and p38 MAPK phosphorylation in both quiescent and proliferative cultures.
However, DS-SILY20 inhibited these increases, presumably through sequestration of the PDGF. Consistent with the complex
responses seen with IFN-γ in SMC physiology in the literature, the response of SMC cultures to IFN-γ was variable and complex.
However, where increased activity was seen with IFN-γ, DS-SILY20 attenuated this activity. Overall, the results suggest that DS-
SILY20 would be an ideal alternative to traditional therapeutics used and may be an effective therapy for the prevention of intimal
hyperplasia after balloon angioplasty.
■ INTRODUCTION
Over the past 10 years, the number of percutaneous coronary
intervention (PCI) procedures performed in the United States
has increased by 33%.1−3 However, thrombosis, neointimal
hyperplasia, and restenosis remain complications of this
procedure, limiting complete functional recovery of the injured
vessel wall. The occurrence of these detrimental consequences
following PCI is attributed to trauma during the procedure,
which triggers an array of mechanical and biological processes
implicated in the healing process. While many different cell
types and processes are implicated within the healing response
of an injured vessel, previous studies have shown that vascular
smooth muscle cells (SMC) activation, migration, and
extracellular matrix (ECM) deposition play important roles in
intimal hyperplasia.4−6
Following balloon injury, SMCs serve as targets for many of
the pro-inflammatory factors released from activated inflam-
matory cells and platelets, as well as injured endothelial cells
and SMCs themselves, stimulating quiescent healthy SMCs to
transform to a proliferative synthetic phenotype.7−10 Platelet-
derived growth factor (PDGF) and interfeuron-γ (IFN-γ) are
two such molecules that activate intracellular transduction
pathways, stimulating SMC proliferation, migration, and ECM
synthesis, ultimately leading to intimal hyperplasia.11−13 PDGF,
which has been demonstrated to increase SMC proliferation
and migration in vitro and in vivo, as well as upregulate SMC
extracellular matrix synthesis, has been associated with the
onset of intimal hyperplasia in arterial-injury models.8,14,14,15
While PDGF is pro-stenotic, the function of IFN-γ with respect
to regulating SMC activity is more complex, with both pro- and
antistenotic activities identified, calling into question the role of
the cytokine on SMC proliferation, migration, and protein
synthesis.16 While IFN-γ exhibits conflicting biological
activities, the cytokine has a range of influence on disease
progression, with recent work providing evidence of an
association of IFN-γ with the onset of intimal hyperplasia.17
In addition to their effects on cell behavior, PDGF and IFN-γ
interact with many proteins and proteoglycans within
tissues.18,19 One such molecule, decorin, a small proteoglycan
consisting of a single glycosaminoglycan (GAG) side chain
linked to a core protein, plays a significant role in the regulation
of SMC migration, proliferation, and extracellular matrix
synthesis19−22 Decorin acts through several different mecha-
nisms to regulate cellular activity, either directly, by
upregulating cyclin-dependent kinase inhibitors, or indirectly,
via interactions with growth factors, such as transforming
growth factor-β (TGF-β) and PDGF, which inhibit the
biological activity associated with these molecules.19,23−25
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While a large focus has been on the interactions of the protein
core with cells, proteins, and signaling molecules,26,27 the GAG
side chain, typically composed of dermatan sulfate (DS), also
contributes to the biological activity associated with the
proteoglycan.28,29 DS binds to a variety of cytokines and
growth factors, including PDGF, TGF-β, and IFN-γ, among
others, and these interactions have been shown to alter the
effects of the signaling molecules on cell behavior.30−33
Previously, our lab designed a mimic of the decorin
proteoglycan.34,35 This mimic, termed DS-SILY20, which
consists of type I collagen-binding peptides bound to a
dermatan sulfate (DS) backbone, has been shown to specifically
bind to type-I collagen, serving as a barrier to platelet adhesion
and activation in vitro and in vivo.35,36 Recently, we
demonstrated that DS-SILY20 directs SMC behavior in a
manner similar to that of decorin; specifically, DS-SILY20 is able
to control SMC migration, protein synthesis, cytokine
secretion, and vascular injury marker production of both
proliferative and quiescent SMCs in vitro.36 Furthermore, we
examined the effects of this molecule on intimal hyperplasia in
Ossabaw swine, demonstrating reduced hyperplasia in injured
vessels treated with DS-SILY20.
36
As both decorin, as well as DS alone, are known to interact
with many growth factors involved in the healing process
following vessel injury, we asked the question of whether DS-
SILY20, which was designed to mimic many of the functions of
decorin, also acted through these mechanisms. In this work, we
investigated the ability of DS-SILY20 to modulate SMC
behavior through interactions with PDGF and IFN-γ. We
demonstrate here the ability of DS-SILY20 to interact with both
PDGF and IFN-γ. Moreover, we examine how the interaction
between DS-SILY20 and PDGF or IFN-γ influences the effects
of these chemical stimuli on SMC proliferation, migration,
protein synthesis, cytokine secretion, and vascular injury marker
production in both proliferative and quiescent SMCs in vitro.
■ EXPERIMENTAL SECTION
DS-SILY20 Synthesis. The decorin mimic (DS-SILY20) was
synthesized as previously described.35 Briefly, vicinal diol groups
present on the backbone of dermatan sulfate (DS, MW 46 275 Da,
Celsus Laboratories) were oxidized via standard periodate oxidation to
form aldehyde moieties. Oxidized DS was then covalently coupled to
the heterobifunctional cross-linker N-[β-maleimidopropionic acid]
hydrazide, trifluoroacetic acid salt (BMPH, Thermo Fisher Scientific)
in phosphate buffered saline (PBS). The collagen-binding peptide
sequence RRANAALKAGELYKSILYGC (noted as SILY, Genscript),
derived from the platelet receptor to type I collagen, was conjugated to
the DS-BMPH compound; specifically, the thiol group on the cysteine
amino acid reacted with the maleimide group of BMPH to form a
thioether bond. Purifications were performed at each step by size
exclusion chromatography and the number of attached peptides was
determined by the consumption of BMPH in the second reaction step.
The final product DS-SILYn, where n indicates the number of attached
SILY peptides, was purified in ultrapure H2O, lyophilized and stored at
−20 °C until use. A biotin-labeled version of the decorin mimic was
also synthesized by reacting 1 mol of SILYbiotin per mole of DS-BMPH
for 1 h, followed by addition of unlabeled SILY to complete the
reaction and form DS-SILYn‑biotin.
Solid Phase Binding Assay. DS-SILY20 was coated (1 μg/well)
onto the surface of a 96-well plate (Nalge Nunc International).
Nonspecific binding was blocked with 1% bovine serum albumin
(BSA) in binding buffer for 1 h at 37 °C. Varying concentrations of
platelet-derived growth factor-BB (PDGF, Peprotech) or interferon-γ
(IFN-γ, Peprotech) in PBS containing 1% BSA were added to the DS-
SILY20 coated surfaces. After a 3 h incubation at 37 °C, plates were
rinsed three times with PBS. PDGF bound to the DS-SILY20-coated
surfaces was detected via biotinylated rabbit anti-PDGF-BB or anti-
IFN-γ antibody (Peprotech) for 2 h at room temperature. Following
rinsing, samples were incubated with streptavidin-HRP, diluted 1:200
in 1% BSA in PBS, for 10 min at room temperature with shaking.
Plates were then rinsed three times with PBS to remove any unbound
streptavidin-HRP prior to the addition of 1:1 hydrogen peroxide/
tetramethylbenzidine, inducing a colorimetric change. After 20 min of
incubation, the reaction was stopped via the addition of 2 N sulfuric
acid and absorbance was read at 540 nm.
Cell Culture. Human coronary artery smooth muscle cells (SMC,
Invitrogen) were cultured in Media 231 (M231, Invitrogen),
supplemented with (all from Invitrogen) 4.9% fetal bovine serum
(FBS), 2 ng/mL basic fibroblast growth factor, 0.5% epidermal growth
factor, 5 ng/mL heparin, 5 μg/mL insulin, and 0.2 μg/mL BSA. Unless
otherwise noted, cells were initially seeded at 5 × 104 cells/cm2 in Ibidi
angiogenesis μ-slide (Ibidi) and allowed to proliferate for 24 h to allow
the formation of multilayered cell constructs. Media was removed and
cultures were treated either with proliferative media, as described
above, or contractile media to induce a quiescent phenotype, for 24 h.
Previously, we have demonstrated that the addition of contractile
media, consisting of M231 supplemented with 1% FBS and 30 μg/mL
heparin, induced SMCs to transition from a proliferative state to a
more differentiated, contractile state due to low serum and
introduction of heparin.37 Treatments were applied to the SMC
cultures. Cells were used between passage numbers 3 and 8 for all
assays and maintained at 37 °C with 5% CO2.
SMC Metabolic Activity. Cultures were incubated in the presence
of 10 ng/mL PDGF or IFN-γ with or without DS-SILY20 for 24 h. The
metabolic activity of the cells was determined using the CellTiter 96
AQueous One Solution Cell Proliferation Assay (Promega). Briefly,
media was mixed with 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxyme-
thoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) and
cultures were reincubated for 2 h at 37 °C with 5% CO2. The media
containing MTS was then transferred into a 96-well plate and
absorbance at 490 nm was measured.
Live/Dead Assay. Cultures were incubated in the presence of 10
ng/mL PDGF or IFN-γ with or without DS-SILY20 for 24 h. To test
cytotoxicity of DS-SILY20, SMC viability was analyzed using LIVE/
DEAD Viability/Cytotoxicity Assay kit (Invitrogen) according to the
manufacturer’s instruction. Briefly, cultures were rinsed with PBS
following treatment and 50 μL of mixed solution of 2 μM Calcein AM
and 2 μM ethidium homodimer-1 was added directly to cells.
Following incubation for 30 min at room temperature, fluorescent
intensity of the cultures was assessed via spectrophotometer to
determine cell viability.
PDGFRβ and IFN-γR1 Phosphorylation. Cells were incubated in
the presence of 10 ng/mL PDGF or IFN-γ with or without DS-SILY20
for 60 min prior to washing with ice cold TBS and solubilized in lysis
buffer (1% NP-40 Alternative, 20 mM Tris, 137 mM NaCl, 10%
glycerol, 2 mM EDTA, 1 mM activated sodium orthovanadate, 10 μg/
mL aprotinin, and 10 μg/mL leupeptin). Lysates were processed at 4
°C for 30 min prior to centrifugation for 5 min at 2000 × g to remove
membrane components. Sandwich ELISAs (all from R&D systems)
were utilized to measure total platelet-derived growth factor receptor-β
(PDGFRβ), total phosphotyrosine PDGFRβ, total interferon-γ
receptor-1 (IFN-γR1), and total phosphotyrosine IFN-γR1. All assays
were performed following the manufacturer’s protocol.
Proliferation. Cells were incubated in the presence of 10 ng/mL
PDGF or IFN-γ with or without DS-SILY20 for 24 h. The effect of DS-
SILY20 on cell proliferation was assessed by determining the number of
cells per volume following treatment. Cultures were fixed with 4%
formaldehyde and nuclei were stained using SYTOX green
(Invitrogen). Cells were visualized using an Olympus FV1000 confocal
microscope with 60× objective. Scans were completed with a xy area
of 512 μm2 and one stack, 14 μm (1 μm per step) in the z-direction,
was taken at three separate locations in each culture. Cell nuclei were
counted, such that cell proliferation was assessed by determining the
number of SMC nuclei per volume.
Migration. SMC migration was examined via a modified Boyden
chamber, using a polycarbonate filter (8.0 μm pore size, Corning) to
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divide the upper and lower chambers. The lower chamber of each well
was filled with serum-free media containing 10 ng/mL PDGF or IFN-
γ. SMCs were trypsinized and resuspended in serum-free media with
or without varying concentrations of DS-SILY20. Cells (5 × 10
4 cells/
cm2) were added to the upper portion of the transwell chamber and
incubated for 5 h at 37 °C. Following incubation, cells were fixed in
4% formaldehyde and nuclei stained with Hoechst 33342. Transwells
were then mounted on glass slides and migratory SMCs visible on the
lower side of the filters were counted by light microscopy using 10×
magnification.
Protein Synthesis. Cells were incubated in the presence of 10 ng/
mL PDGF or IFN-γ with or without DS-SILY20 for 24 h. To determine
the effects of DS-SILY20 on protein synthesis in both proliferative and
differentiated SMC cultures, click chemistry was utilized to
fluorescently label newly synthesized proteins.38 After washing the
cells once with PBS, cells were incubated at 37 °C for 60 min with
serum-free media to deplete methionine reserves. Cultures were then
supplemented with 1 μM L-azidohomoalanine (AHA, Invitrogen) in
serum-free media for 4 h. Cells were then rinsed with PBS to remove
any excess AHA and incubated with coculture media overnight to
allow protein production. Cultures were fixed with 4% formaldehyde,
permeabilized with 0.25% Triton X-100 in PBS, and blocked with 1%
BSA in PBS. To detect the newly synthesized proteins containing
AHA, alkyne-labeled Alexa Fluor 594 (AF-594, Invitrogen) was
selectively bound via copper-catalyzed azide−alkyne ligation. Cell
nuclei were stained using SYTOX green.
Proteins were visualized using an Olympus FV1000 confocal
microscope with 60× objective. Scans were completed with a xy area
of 512 μm2 and one stack, 14 μm (1 μm per step) in the z-direction,
was taken at three separate locations in each culture. Each stack was
taken at the same exposure settings to ensure similar darkness values;
cultures lacking AHA-treatment were utilized as controls. ImageJ was
used to determine the average fluorescent intensity of each stack based
on AF-594 fluorescence. Average fluorescent intensity of each stack
was then normalized to the number of cells in the 3D image.
Real-Time PCR. SMC cultures were incubated in the presence of
10 ng/mL PDGF with or without DS-SILY20 for 24 h. Following
treatment, total RNA was harvested utilizing a Nucleospin Total RNA
Isolation Kit (Clontech) according to the manufacturers’ recom-
mendations; to eliminate contamination with genomic DNA, DNase
digestion was performed for 15 min. Extracted RNA was quantified via
a Nanodrop 2000 spectrophotometer (Thermo Scientific) and reverse
transcribed into complementary DNA (cDNA) with a High Capacity
cDNA Reverse Transcription Kit (Life Technologies). Real-time PCR
(qPCR) was performed on a 7500 Real-Time PCR machine (Applied
Biosystems) using the Taqman gene expression assays with the
following ID numbers (all from Applied Biosystems): Collagen 1α2,
Hs00164099_m1; Collagen 3α1, Hs00943809_m1; Fibronectin,
Hs00365052_m1; and β-actin, Hs99999903_m1. cDNA amplification
was performed with an initial denaturation step of 10 min at 95 °C,
followed by 40 cycles consisting of 15 s denaturation interval at 95 °C
and a 1 min interval for annealing and primer elongation at 60 °C. The
point at which PCR product was first detected above a fixed threshold
(termed the cycle threshold, Ct), was determined for each sample.
Changes in the expression of the target gene were calculated using
2−ΔΔCt, where ΔΔCt = (Cttarget − Ctβ‑actin)sample − (Cttarget −
Ct
β‑actin)control. Three independent PCR reactions were performed for
each treatment.
Cytokine Production. Cells were incubated in the presence of 10
ng/mL PDGF or IFN-γ with or without DS-SILY20 for 24 h. Media
was removed from the cultures and a Pro-Inflammatory I kit (Meso
Scale Discovery) was used to analyze cytokine production of SMCs
according to manufacturer’s instructions. Briefly, plates were warmed
to room temperature and incubated with 25 μL of samples and
standards for 2 h at room temperature with vigorous shaking. The
detection antibody was then added to the plate and incubated for 2 h
at room temperature with vigorous shaking. After washing three times
with PBS with 0.05% Tween-20, 2× read buffer was added to the plate
and imaged using a Sector Imager 2400A (Meso Scale Discovery). The
pro-inflammatory markers interleukin-1β(IL-1β), interleukin-6 (IL-6),
and tumor necrosis factor-α(TNF-α) were examined in this study.
Data were analyzed using the MSD Discovery Workbench Software.
Thrombomodulin Production. Following treatment with 10 ng/
mL PDGF or IFN-γ with or without DS-SILY20 for 24 h, cells were
washed twice with ice cold PBS and solubilized in lysis buffer (9 M
urea, 4% CHAPS, and phosphatase inhibitor cocktail-1 in Millipore
water). Lysates were processed at 4 °C for 30 min prior to
centrifugation for 20 min at 18000 × g to remove membrane
components. A BCA assay protein kit (Pierce) was used to quantify
total protein. A Vascular Injury Marker I kit (Meso Scale Discovery)
was used to analyze thrombomodulin production of SMCs according
to manufacturer’s instructions. Briefly, plates were warmed to room
temperature and incubated with 10 μL of samples and standards for 2
h at room temperature with vigorous shaking. Following gentle rinsing
of the wells, the detection antibody was then added and incubated for
1 h at room temperature with vigorous shaking. After washing three
times with PBS with 0.05% Tween-20, 2× read buffer was added to the
plate and imaged using a Sector Imager 2400A. Data were analyzed
using the MSD Discovery Workbench Software.
MAPK Phosphorylation. The phosphorylation of mitogen-
activated protein kinases (MAPK), including extracellular signal-
related kinase (ERK), c-Jun NH2-terminal kinase (JNK), and p38
MAPK (p38), was examined. Cells were incubated in the presence of
10 ng/mL PDGF or IFN-γ with or without DS-SILY20 for 10 or 60
min prior to washing with ice cold tris buffered saline (TBS) and
solubilized in lysis buffer (150 mM NaCl, 20 mM Tris, 1 mM EDTA, 1
mM EGTA, 1% Triton-X-100, plus protease inhibitors and
phosphatase inhibitors). Lysates were processed at 4 °C for 30 min
prior to centrifugation for 20 min at 18000 × g to remove membrane
components. Phospho-JNK (Thr183/Tyr185), phospho-p38
(Thr180/Tyr182), and phospho-ERK-1/2 (Thr/Tyr: 202/204; 185/
187) levels were evaluated using the MAP Kinase Whole Cell Lysate
kit (Meso Scale Discovery); Total JNK, p38, and ERK-1/2 were
determined via MAP Kinase (Total Protein) Whole Cell Lysate Kit
(Meso Scale Discovery), according to manufacturer’s instructions.
Briefly, plates were warmed to room temperature and incubated with
25 μL of samples for 3 h at room temperature with vigorous shaking.
Following gentle rinsing of the wells, the detection antibody was then
added and incubated for 1 h at room temperature with vigorous
shaking. After washing three times with TBS, 2× read buffer was added
to the plate and imaged using a Sector Imager 2400A. Data were
analyzed using the MSD Discovery Workbench Software. The relative
amount of phosphorylated JNK, p38, and ERK-1/2 were normalized
to total JNK, p38, and ERK-1/2 for each sample.
Statistical Analysis. Results are expressed as means ± standard
error. Statistical analysis was performed using SAS software (SAS
Institute). All results were analyzed using ANOVA with Tukey HSD
posthoc test. The threshold for statistical significance was set at p <
0.05.
■ RESULTS
Solid Phase Binding Assay. To assess the ability of PDGF
and IFN-γ to bind to DS-SILY20, a solid phase assay with
immobilized DS-SILY20 and increasing amounts of the soluble
growth factor was employed. PDGF and IFN-γ interactions
with DS-SILY20 were dose-dependent and saturable (Figure
1A,B). The interaction between DS-SILY20 and PDGF or IFN-γ
in the solid phase assay was characterized via the Hedborn and
Heinegard approach and Scatchard-type plots were drawn
(Figure 1A,B, insets).39 Dissociation constant (Kd) values,
calculated on the basis of Scatchard graph equations, indicate
that PDGF has an affinity of 32.2 ± 5.7 nM for DS-SILY20,
while IFN-γ exhibited a lower affinity for the mimic of 55.1 ±
6.9 nM.
Metabolic Activity and Cytotoxicity. To better under-
stand the effects of DS-SILY20 with and without PDGF or IFN-
γ on SMC behavior, both proliferative and quiescent SMC
cultures were used to assess the injured and uninjured SMC
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phenotype, respectively. The different SMC phenotypes were
induced via changes in media components, as previously
demonstrated elsewhere.37 Using the CellTiter 96 AQueous One
Solution Cell Proliferation Assay and the LIVE/DEAD
Viability/Cytotoxicity Assay, no changes in SMC metabolic
activity or viability were exhibited with the addition of PDGF or
IFN-γ with any concentration of DS-SILY20 (Figures S1 and S2,
Supporting Information). This general trend was demonstrated
by both the proliferative and quiescent cultures, as compared to
controls.
PDGFRβ and IFN-γR1 Phosphorylation. To assess the
ability of DS-SILY20 to modulate PDGF and IFN-γ signaling,
phosphorylation of PDGFRβ and IFN-γR1 was investigated.
The addition of 10 μM DS-SILY20 to proliferative or quiescent
SMCs did not alter phospho-PDGFRβ compared to no
treatment controls (Figure 2A,B). Phospho-PDGFRβ levels
were significantly increased in both proliferative and quiescent
SMCs with PDGF treatment. Interestingly, the addition of DS-
SILY20 to PDGF-stimulated SMCs resulted in significantly
decreased phosphorylation of the PDGF receptor in quiescent
cultures compared to cultures stimulated with PDGF alone.
While DS-SILY20 alone did not effect phosphorylation of
PDGFRβ, the decorin mimic did significantly decrease relative
phospho-IFN-γR1 levels in both proliferative and quiescent
cultures compared to no treatment controls (Figure 2C,D). As
expected, the addition of IFN-γ to proliferative and quiescent
SMCs significantly increased phosphorylation of IFN-γR1.
However, the ability of IFN-γ to induce phosphorylation of its
receptor was significantly hindered when IFN-γ-stimulated
cultures were treated with DS-SILY20.
Proliferation. SMC proliferation was assessed by determin-
ing the number of SMC nuclei per cell culture volume
following the culture period. Similar to previous work,
significantly increased numbers of SMC cells were found in
proliferative cultures compared to quiescent cultures (Table
1).36 For proliferative SMC cultures, the addition of 10 μM DS-
SILY20 resulted in decreased proliferation compared to
controls; however, no change in proliferation was exhibited in
quiescent SMC cultures with addition of 10 μM DS-SILY20.
To examine the influence of DS-SILY20 on SMC-growth
factor interactions, the effect of PDGF and IFN-γ on SMC
proliferation was further assessed. PDGF added to proliferative
cultures induced a significant increase in SMC proliferation. A
dose-dependent inhibition of PDGF-stimulated SMC prolifer-
ation resulted as the concentration of DS-SILY20 increased in
proliferative cultures; ultimately culminating with a 23%
decrease in proliferation, compared to PDGF-stimulated
SMCs. Interestingly, the addition of IFN-γ to proliferative
cultures did not alter SMC proliferation. However, as the
concentration of DS-SILY20 increased in IFN-γ-stimulated
proliferative cultures, a reduction in proliferation was still
observed, with cultures treated with 10 μM DS-SILY20
displaying a significant reduction in proliferation compared to
no treatment controls.
The impact of PDGF and IFN-γ on quiescent SMCs, both in
the presence and absence of DS-SILY20, was also probed. A
significant increase in SMC proliferation was observed when
cultures were treated with either PDGF or IFN-γ, as compared
to no treatment controls. Moreover, again a dose-dependent
inhibition of SMC proliferation resulted as the concentration of
DS-SILY20 increased in cultures treated with either PDGF or
IFN-γ. The addition of 0.1, 1, or 10 μM DS-SILY20 to PDGF-
stimulated SMCs resulted in significantly decreased prolifer-
ation compared to no treatment controls. Conversely, even at
the highest concentration of DS-SILY20, IFN-γ-stimulated SMC
proliferation remained significantly increased compared to no
treatment controls. However, in cultures treated with 10 μM
DS-SILY20, IFN-γ induced proliferation was significantly
reduced by 36% compared to quiescent cultures treated IFN-
γ alone.
Migration and Cell Morphology. SMC migration was
examined using a modified Boyden chamber.40 Similar to
previous work, significantly increased migration was exhibited
by SMCs in a proliferative phenotype compared to SMCs in a
contractile phenotype (Figure 3).36 Furthermore, the addition
of 10 μM DS-SILY20 resulted in significantly reduced migration
in both proliferative and quiescent SMCs. The effect of DS-
SILY20 on growth factor-stimulated SMC migration was also
examined. Proliferative SMCs incurred a significant increase in
migration with PDGF treatment (Figure 3A). However, the
addition of DS-SILY20 caused a dose-dependent inhibition of
PDGF-stimulated SMC migration in proliferative SMCs, where
PDGF-stimulated cultures treated with 10 μM DS-SILY20
exhibited a 94% decrease in migration compared to proliferative
SMCs stimulated with PDGF alone. Furthermore, proliferative
PDGF-stimulated SMCs treated with 1 or 10 μM DS-SILY20
demonstrated decreased migration to a level similar to that of
quiescent SMCs. Interestingly, the addition of IFN-γ to
proliferative cultures did not alter SMC migration (Figure
3B). However, as the concentration of DS-SILY20 increased in
IFN-γ-stimulated cultures, SMC migration was still inhibited in
Figure 1. Binding profiles of DS-SILY20 to PDGF and IFN-γ.
Saturation binding of (A) PDGF and (B) IFN-γ to DS-SILY20.
Immobilized DS-SILY20 was incubated with increasing amounts of
PDGF or IFN-γ. The growth factor binding was determined by using
biotin-conjugated rabbit-antihuman PDGF or rabbit-antihuman IFN-γ,
followed by streptavidin-HRP colorimetric reaction. Insets show a
Scatchard-type plot of the experimental data for PDGF and IFN-γ
binding to DS-SILY20. Dissociation constants (Kd) were calculated by
Scatchard analysis. PDGF binding to particular GAG was analyzed in
five experiments. Results of one representative experiment for each
GAG are shown.
Biomacromolecules Article
dx.doi.org/10.1021/bm500224f | Biomacromolecules 2014, 15, 2090−21032093
a dose-dependent manner, where cultures treated with 0.1, 1,
and 10 μM DS-SILY20 displayed a significant reduction in
migration compared to both no treatment controls and
proliferative cultures treated with IFN-γ alone.
Similar to proliferative SMCs, the addition of PDGF to
quiescent SMC cultures resulted in a significant increase (∼5-
fold) in SMC migration compared to no treatment controls
(Figure 3C). Likewise, exposure of IFN-γ to quiescent SMC
cultures also resulted in a significant increase in SMC migration
compared to no treatment controls (Figure 3D). A significant
decrease in SMC migration was also observed in PDGF- or
IFN-γ-stimulated quiescent SMCs treated with 10 μM DS-
SILY20; however, no change in the number of migratory SMCs
was observed at lower concentrations of DS-SILY20 when cells
were stimulated with either PDGF or IFN-γ.
Consistent with altered cell migration, changes in cell
morphology were also observed. Proliferative SMCs exhibited
a more unorganized, rhomboid-like morphology, which was
further intensified by treatment with PDGF and IFN-γ (Figure
S3, Supporting Information). However, the addition of DS-
SILY20 to proliferative cultures resulted in more aligned,
spindle-like SMCs, similar to that of quiescent SMCs. The
addition of PDGF and IFN-γ to quiescent cultures resulted in
SMCs exhibiting unorganized, rhomboid-like morphological
features. DS-SILY20 treatment to PDGF- or IFN-γ-stimulated
quiescent SMCs resulted in more organized, spindle-like SMCs.
Figure 2. DS-SILY20 regulates phosphorylation of PDGF or IFN-γ receptors in stimulated SMCs. Relative phosphorylated (A, B) PDGFRβ or (C,
D) IFN-γR1 produced in (A, C) proliferative and (B, D) quiescent SMCs treated with 10 ng/mL (A, B) PDGF or (C, D) IFN-γ with or without DS-
SILY20. The relative amount of phosphorylated PDGFRβ and IFN-γR1 was normalized to total PDGFRβ and IFN-γR1 for each sample, respectively.
* Represents significance from control nontreated cells; # Represents significance either PDGF- or IFN-γ-treated cultures (N > 3).
Table 1. Proliferation and Protein Expression of Proliferative and Quiescent SMCs Treated with PDGF or IFN-γ and DS-SILY20
proliferation (cells/mm3) protein expression (fluorescence/cell (×103))
treatment proliferative SMC quiescent SMC proliferative SMC quiescent SMC
no treatment 15.3 ± 0.7b 6.8 ± 0.4b,c 71.7 ± 4.8b,c 34.1 ± 1.8b,c
10 μM DS-SILY20 11.5 ± 1.3
b 6.2 ± 0.5b,c 59.9 ± 5.0a,b 32.8 ± 1.3b,c
10 ng/mL PDGF + μM DS-SILY20
0 19.1 ± 1.2a 9.6 ± 0.8a 86.3 ± 10.3a 45.3 ± 4.3a
0.01 17.9 ± 1.7a 8.9 ± 0.8a 78.9 ± 3.8a 33.3 ± 2.7b
0.1 16.9 ± 0.8b 7.9 ± 0.6b 72.3 ± 4.7 28.7 ± 3.5b
1 15.8 ± 1.2b 7.4 ± 0.3b 68.4 ± 4.6b 26.2 ± 2.3a,b
10 14.8 ± 1.4b 6.9 ± 0.7b 63.3 ± 3.7b 23.0 ± 2.6a,b
10 ng/mL IFN-γ + μM DS-SILY20
0 15.1 ± 1.1 9.3 ± 1.0a 55.0 ± 9.4a 61.5 ± 4.3a
0.01 14.3 ± 2.7 9.2 ± 0.6a 55.5 ± 8.3a 52.9 ± 7.4a
0.1 14.2 ± 0.8 9.0 ± 0.7a 49.1 ± 4.2a 53.4 ± 2.5a,c
1 14.8 ± 1.1 8.8 ± 0.9a 45.5 ± 5.6a 45.a,c4 ± 4.3
10 13.5 ± 0.6a 8.1 ± 1.1 42.4 ± 4.5a 39.4 ± 1.6a,c
aSignificance from no treatment control cultures. bSignificance from PDGF-stimulated SMC cultures. cSignificance from IFN-γ stimulated SMC
cultures.
Biomacromolecules Article
dx.doi.org/10.1021/bm500224f | Biomacromolecules 2014, 15, 2090−21032094
Protein Synthesis. As excess protein synthesis is also
implicated in intimal hyperplasia, de novo protein synthesis
following DS-SILY20 treatment, and doping with AHA, was
analyzed by detecting the presence of the incorporated AHA
within proteins via copper-catalyzed click chemistry reaction,
which attached a fluorescent tag directly to the unnatural amino
acid. By quantification of fluorescent intensity, proliferative
SMC cultures were found to synthesize approximately ∼2-fold
more protein compared to quiescent cultures (Table 1). In
proliferative SMC cultures, a significant decrease in protein
expression was observed in cultures treated with 10 μM DS-
SILY20, where approximately 17% less protein was synthesized
compared to control proliferative cultures; protein synthesis in
quiescent cultures was not altered with the addition of 10 μM
DS-SILY20.
The effect of DS-SILY20 on growth factor-stimulated protein
synthesis from proliferative and quiescent SMCs was also
probed. Treatment with PDGF significantly increased protein
synthesis for SMCs exhibiting a proliferative phenotype. The
addition of DS-SILY20 to PDGF-stimulated cultures triggered a
dose-dependent inhibition of protein expression in proliferative
SMCs, ultimately culminating in a 27% decrease in protein
synthesis compared to proliferative SMCs treated with PDGF
alone. Moreover, proliferative cultures treated with high
Figure 3. DS-SILY20 regulates PDGF- or IFN-γ-induced SMC migration. Migration of (A, B) proliferative and (C, D) quiescent SMCs treated with
10 ng/mL (A, C) PDGF or (B, D) IFN-γ with or without DS-SILY20. SMC migration was examined via a modified Boyden chamber, where SMCs
were treated with PDGF or IFN-γ with or without DS-SILY20. Following incubation, cells were fixed formaldehyde and nuclei stained with Hoechst,
to identify migratory SMCs. * Represents significance from control nontreated cells; # represents significance either PDGF- or IFN-γ-treated
cultures (N > 6).
Figure 4. SMC matrix gene expression altered with PDGF and DS-SILY20. Genetic expression of (A, D) collagen I, (B, E) collagen III, and (C, F)
fibronectin in (A−C) proliferative and (D−F) quiescent SMCs in response to treatment with PDGF and DS-SILY20. Data normalized to no
treatment controls. * Represents significance from control nontreated cells; # represents significance either PDGF-treated cultures (N > 3).
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concentrations of DS-SILY20 synthesized protein quantities
similar to no treatment controls. Unlike PDGF, the addition of
IFN-γ to proliferative cultures significantly reduced protein
synthesis. The addition of DS-SILY20 to IFN-γ treated
proliferative cultures further reduced protein expression;
ultimately culminating with a 41% decrease in protein synthesis
compared to no treatment controls.
As expected, stimulation of quiescent SMCs with PDGF or
IFN-γ resulted in significantly increased protein expression
compared to no treatment controls. A dose-dependent decrease
in protein expression was observed in PDGF- or IFN-γ-
stimulated quiescent SMCs with increasing concentrations of
DS-SILY20. PDGF-induced protein synthesis was significantly
decreased in quiescent SMCs treated with any concentration of
DS-SILY20 compared to cultures stimulated with PDGF alone.
Likewise, protein expression was significantly decreased with
the addition of 0.1, 1, or 10 μM DS-SILY20 to IFN-γ-stimulated
cultures compared to quiescent SMCs treated with IFN-γ
alone. Furthermore, at the highest DS-SILY20 concentrations
utilized, PDGF-stimulated protein expression was significantly
inhibited, as compared to quiescent no treatment controls.
However, even at the highest concentration of DS-SILY20
utilized, protein synthesis in IFN-γ-stimulated SMCs remained
significantly increased compared to no treatment controls.
Genetic Expression of Collagens and Fibronectin.
Increased protein expression was observed in SMC cultures
treated with PDGF (Table 1). As collagen I, collagen III, and
fibronectin are differentially expressed ECM proteins within
intimal hyperplastic tissue, changes in gene expression of these
proteins were examined in PDGF and DS-SILY20 treated SMC
cultures via qPCR (Figure 4). For proliferative SMC cultures,
the addition of DS-SILY20 significantly reduced the expression
of fibronectin mRNA and the increased expression of collagen
III genes (Figure 4A−C). Proliferative SMC cultures exposed
to PDGF demonstrated significant upregulation of collagen I
and fibronectin mRNA, while collagen III gene expression
levels were downregulated. The reduction of collagen III
mRNA expression due to PDGF exposure was circumvented
Figure 5. DS-SILY20 attenuates PDGF stimulated cytokine secretion in SMCs. Expression of (A, D) IL-1β, (B, E) IL-6, and (C, F) TNF-α from (A,
B, C) proliferative and (D, E, F) quiescent SMCs in response to 10 ng/mL PDGF with or without DS-SILY20. Cytokines produced by cultured
SMCs were measured 24 h post-treatment via. * Represents significance from control nontreated cells; # represents significance either PDGF-treated
cultures (N > 6).
Figure 6. DS-SILY20 controls IFN-γ stimulated cytokine SMC production. Expression of (A, D) IL-1β, (B, E) IL-6, and (C, F) TNF-α from (A, B,
C) proliferative and (D, E, F) quiescent SMCs in response to 10 ng/mL IFN-γ with or without DS-SILY20. Cytokines produced by cultured SMCs
was measured 24 h post-treatment. * Represents significance from control nontreated cells; # represents significance either IFN-γ-treated cultures (N
> 6).
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with DS-SILY20 addition, where the genetic expression of
collagen III was significantly increased compared to both
proliferative controls and SMCs treated with PDGF alone.
Furthermore, the addition of DS-SILY20 to PDGF-stimulated
cultures significantly decreased expression of fibronectin and
collagen I mRNA compared to SMCs treated with PDGF
alone.
The genetic expression of collagen I in quiescent SMCs was
not altered with DS-SILY20 treatment compared to quiescent
no treatment controls; however, the addition of DS-SILY20
significantly increased collagen III gene expression and reduced
the expression of fibronectin mRNA (Figure 4D−F). PDGF
significantly down-regulated both collagen III and fibronectin
mRNA, compared to quiescent no treatment controls. Collagen
I gene expression was not altered by the addition of PDGF with
or without DS-SILY20 cotreatment. However, when quiescent
SMCs were cotreated with PDGF and 10 μM DS-SILY20,
collagen III and fibronectin mRNA expression increased
compared to cultures exposed to PDGF alone.
Cytokine Production. Following vessel injury, stimulated
SMCs actively participate in the inflammatory cascade,
producing, and secreting a range of factors, including IL-1β,
IL-6, and TNF-α.7,8 Thus, expression of IL-1β, IL-6, and TNF-
α from SMC cultures following treatment with PDGF or IFN-γ
was examined via MSD Sector Imager. Examination of
nontreated control cultures revealed that proliferative SMCs
exhibited increased levels of IL-1β and TNF-α compared to
quiescent cultures; however, the two cultures produced similar
levels of IL-6 (Figures 5 and 6). The addition of DS-SILY20 to
either SMC cultures exhibiting either phenotype resulted in
significant reductions in IL-1β, IL-6, and TNF-α expression.
The effect of DS-SILY20 on the production of pro-
inflammatory cytokines following PDGF or IFN-γ stimulation
was evaluated in both proliferative and quiescent SMC cultures.
PDGF addition to proliferative SMCs significantly increased IL-
1β and TNF-α production; however, IL-6 levels did not change
compared to controls (Figure 5A−C). A general trend was
observed such that as the concentration of DS-SILY20
increased, cytokine production in PDGF-stimulated SMCs
decreased, where significant reductions in IL-1β, IL-6, and
TNF-α expression were observed at the highest levels of DS-
SILY20 tested, compared to proliferative cultures treated with
PDGF alone. At 10 μM DS-SILY20, production of IL-1β and
TNF-α in PDGF-stimulated cultures was reduced to levels
similar to that of no treatment controls, while IL-6 expression
was significantly decreased compared to controls. The addition
of IFN-γ to proliferative cultures resulted in increased IL-1β
production; however, no changes in IL-6 and TNF-α
expression were exhibited (Figure 6A−C). When proliferative
cultures were cotreated with IFN-γ and DS-SILY20, a dose-
dependent inhibition of IL-1β production occurred as the
concentration of DS-SILY20 increased. Conversely, DS-SILY20
did not influence TNF-α production in IFN-γ-stimulated
proliferative SMCs. Interestingly, IL-6 expression was only
significantly decreased in proliferative cultures treated with
IFN-γ and 10 μM DS-SILY20.
Similar to proliferative SMCs, the addition of PDGF to
quiescent cultures significantly increased IL-1β and TNF-α
production; however, IL-6 levels did not change compared to
controls (Figure 5D−F). High concentrations of DS-SILY20
mitigated the increase in IL-1β and TNF-α produced from
quiescent SMCs exposed to PDGF; however, no change in IL-
Figure 7. DS-SILY20 regulates PDGF- or IFN-γ-induced SMC thrombomodulin production. Thrombomodulin expression from (A, B) proliferative
and (C, D) quiescent SMCs treated with 10 ng/mL (A, C) PDGF or (B, D) IFN-γ with or without DS-SILY20. Thrombomodulin produced by
cultured SMCs was measured 24 h post-treatment following cell lysis. * Represents significance from control nontreated cells; # represents
significance either PDGF- or IFN-γ-treated cultures (N > 6).
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1β and TNF-α expression from PDGF-stimulated cultures was
observed at lower concentrations of DS-SILY20, compared to
quiescent controls. Cytokine expression was not altered in
quiescent SMCs stimulated with IFN-γ alone (Figure 6D−F).
However, IL-1β and TNF-α production in quiescent SMCs
significantly increased when cultures were cotreated with IFN-γ
and low concentrations of DS-SILY20. However, this effect was
mitigated at high concentrations of DS-SILY20, where cytokine
production was similar to no treatment controls. IL-6
production in quiescent SMCs was not altered by treatment
with IFN-γ, with or without DS-SILY20 cotreatment.
Thrombomodulin Expression. Following vessel injury,
the production of thrombomodulin by endothelial cells and
SMCs decreases the thrombogenic potential of the damaged
tissue. Thrombomodulin produced by SMCs in culture was
analyzed via MSD Sector Imager. Control nontreated
proliferative SMCs cultures exhibited significantly increased
amounts of thrombomodulin compared to quiescent SMC
cultures (Figure 7). In proliferative SMC cultures, a significant
increase in thrombomodulin production was observed in
cultures treated with 10 μM DS-SILY20; however, thrombo-
modulin expression in quiescent cultures was not altered with
the addition of 10 μM DS-SILY20.
The addition of PDGF or IFN-γ to proliferative cultures
stimulated thrombomodulin production (Figure 7A,B). The
addition of 0.01 μM DS-SILY20 to PDGF- or IFN-γ-stimulated
cultures significantly decreased thrombomodulin expression
compared to cultures stimulated with either growth factor
alone. However, at higher concentrations of DS-SILY20,
thrombomodulin expression in PDGF- or IFN-γ-stimulated
SMCs increased to levels similar to proliferative cultures
stimulated with growth factor alone.
Quiescent SMCs also exhibited increased thrombomodulin
following PDGF stimulation; however, IFN-γ had no effect on
thrombomodulin production in quiescent cultures (Figure
7C,D). Interestingly, no change in thrombomodulin production
was exhibited in quiescent PDGF-stimulated SMCs with the
addition of any concentration of DS-SILY20, compared to no
treatment controls. Likewise, thrombomodulin expression was
not altered in quiescent SMC cultures cotreated with IFN-γ and
DS-SILY20.
MAPK Phosphorylation. MAPKs, including ERK, JNK,
and p38, are important intracellular transduction pathways
involved in vascular remodeling and disease.41−43 To determine
the relative amount of phosphorylated ERK-1/2 (pERK-1/2),
JNK (pJNK), and p38 (pp38), quiescent and proliferative
SMCs were stimulated with 10 ng/mL PDGF or IFN-γ with or
without DS-SILY20 for 10 min or 1 h. Cell lysates were then
analyzed via MSD Sector Imager to determine the relative
phosphorylation levels of the intracellular signaling molecules
(Figures 8 and 9). No significant changes in pJNK were
observed for any treatments at the time points examined (data
not shown).
Phosphorylation of ERK-1/2 has previously been correlated
with increased SMC migration.44 Thus, we sought to correlate
the changes observed in migration (Figure 3) with pERK-1/2
phosphorylation levels. After 10 min of stimulation, the
addition of 10 μM DS-SILY20 to proliferative SMCs
significantly decreased pERK-1/2 compared to no treatment
controls (Figure 8A). However, pERK-1/2 levels were not
Figure 8. DS-SILY20 regulates PDGF- or IFN-γ-induced ERK-1/2 phosphorylation in SMCs. Relative phosphorylated ERK-1/2 produced in (A, B)
proliferative and (C, D) quiescent SMCs treated with 10 ng/mL (A, C) PDGF or (B, D) IFN-γ with or without DS-SILY20. The relative amount of
phosphorylated ERK was normalized to total ERK for each sample. * Represents significance from control nontreated cells; # represents significance
either PDGF- or IFN-γ-treated cultures (N > 5).
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altered with the addition of PDGF to proliferative SMCs. For
proliferative cultures, the addition of DS-SILY20 to PDGF-
stimulated SMCs resulted in a dose dependent decrease in
pERK-1/2 compared to cultures stimulated with PDGF alone.
Furthermore, the addition of 10 μM DS-SILY20 significantly
decreased pERK-1/2 levels compared to both no treatment and
PDGF-stimulated cultures. The addition of IFN-γ to
proliferative cultures did not affect pERK-1/2 levels (Figure
8B). However, as the concentration of DS-SILY20 increased
within IFN-γ-stimulated SMCs, a dose dependent decrease of
pERK-1/2 was still observed. Interestingly, relative levels of
pERK-1/2 in proliferative cultures returned to levels similar to
that of no treatment controls after 60 min of stimulation,
independent of treatment and phenotype (data not shown).
In contrast to proliferative SMC cultures, after 10 min of
treatment pERK-1/2 was not altered in quiescent SMCs dosed
with 10 μM DS-SILY20 treatment (Figure 8C). However,
pERK-1/2 was significantly increased in PDGF-treated
quiescent cultures compared to no treatment controls. For
quiescent cultures, the addition of DS-SILY20 to PDGF-
stimulated SMCs resulted in a dose dependent decrease in
pERK-1/2 compared to cultures stimulated with PDGF alone.
Furthermore, the addition of 10 μM DS-SILY20 significantly
decreased pERK-1/2 levels compared to both no treatment and
PDGF-stimulated cultures after 10 min of stimulation. The
addition of IFN-γ to quiescent cultures did not affect pERK-1/2
levels (Figure 8D). Interestingly, pERK-1/2 levels in IFN-γ-
stimulated quiescent SMCs significantly increased in cultures
treated with the lowest concentrations of DS-SILY20 and IFN-γ,
compared to no treatment controls. However, as the
concentration of DS-SILY20 increased in IFN-γ-stimulated
cultures, pERK-1/2 significantly decreased. Similar to results
observed for proliferative cultures, relative levels of pERK-1/2
in quiescent cultures treated with IFN-γ and DS-SILY20
returned to levels similar to that of no treatment controls
after 60 min of stimulation; however, elevated levels of pERK-
1/2 were still observed in quiescent SMCs stimulated with
PDGF alone or PDGF and low concentrations of DS-SILY20
(data not shown).
Several studies have correlated phosphorylation of p38 with
increased inflammatory cytokine expression.45−47 Thus, we
sought to correlate the changes observed in cytokine expression
(Figures 5 and 6) with p38 phosphorylation levels. Contrasting
results were seen when stimulating with DS-SILY20. The
addition of 10 μM DS-SILY20 to proliferative SMCs
significantly decreased pp38 compared to no treatment
controls, after 10 min of stimulation, while pp38 was not
altered in quiescent SMCs dosed with 10 μM DS-SILY20
treatment (Figure 9). The addition of PDGF to SMC cultures
elicited significant increases in pp38, independent of
phenotype, after 10 min (Figure 9A,B). Enhanced pp38 levels,
due to PDGF treatment, were mitigated with the addition of
DS-SILY20 to either phenotype, where a dose-dependent
decrease in pp38 was observed as DS-SILY20 concentrations
increased in PDGF-stimulated cultures. The addition of IFN-γ
to either proliferative or quiescent SMC cultures did not alter
pp38 levels after 10 min of stimulation (Figure 9C,D). The
addition of DS-SILY20 to IFN-γ-stimulated quiescent cultures
did not alter pp38 levels compared to no treatment controls,
even at the highest concentrations of DS-SILY20 utilized. No
changes in pp38 levels were exhibited in proliferative SMCs
cotreated with IFN-γ and low concentrations of DS-SILY20;
however, pp38 levels were significantly reduced in IFN-γ-
stimulated cultures treated with 10 μM DS-SILY20, compared
Figure 9. DS-SILY20 attunes p38 phosphorylation in PDGF- or IFN-γ-stimulated SMCs. Relative phosphorylated p38 produced in (A, C)
proliferative and (B, D) quiescent SMCs treated with 10 ng/mL (A, B) PDGF or (C, D) IFN-γ with or without DS-SILY20. The relative amount of
phosphorylated p38 was normalized to total p38 for each sample. * Represents significance from control nontreated cells; # represents significance
either PDGF- or IFN-γ-treated cultures (N > 5).
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to no treatment controls. Interestingly, relative levels of pp38 in
both proliferative and quiescent cultures returned to levels
similar to that of no treatment controls after 60 min of
stimulation, independent of treatment and phenotype (data not
shown).
■ DISCUSSION
A detrimental consequence following PCI is injury to the vessel
wall during balloon expansion, which triggers an array of
mechanical and biological processes, leading to the occurrence
of thrombosis, neointimal hyperplasia, and restenosis.48
Biochemical stimuli, such as growth factors and cytokines,
produced by platelets, inflammatory cells, SMCs, and
endothelial cells following vessel injury activate intracellular
transduction pathways, stimulating SMC proliferation, migra-
tion, and ECM synthesis, ultimately leading to intimal
hyperplasia.8,11,14 Activated platelets release both PDGF and
IFN-γ following vascular injury that occurring during balloon
angioplasty. Further, both play important roles in vascular
repair, and have been implicated in the development of intimal
hyperplasia.14,16 Therapeutics able to control SMC prolifer-
ation, migration, and ECM production that lead to intimal
hyperplasia, and that also allow for endothelium regeneration,
are needed to improve outcomes following balloon angioplasty.
We have previously demonstrated that DS-SILY20 inhibits
platelet binding to vessels walls following balloon angioplasty,
and further showed that intimal hyperplasia was reduced 28
days following injury in vivo.36 To further delineate
mechanisms through which DS-SILY20 suppresses intimal
hyperplasia, we sought to understand the interactions between
PDGF or IFN-γ and DS-SILY20 in proliferative and quiescent
SMC cultures. We demonstrate here that the antithrombotic
biomolecule, DS-SILY20, binds to PDGF and IFN-γ and limits
the effects of the growth factors on altered SMC morphology,
proliferation, migration, protein synthesis, cytokine secretion,
and vascular injury marker production in both proliferative and
quiescent SMCs in vitro.
We first set out to assess potential effects of DS-SILY20 on
SMCs. No measurable changes in metabolic activity or cell
viability were observed in either proliferative or quiescent SMC
cultures following PDGF or IFN-γ treatment with and without
DS-SILY20 (Figures S1 and S2, Supporting Information). Thus,
the inhibitory effect of DS-SILY20 on PDGF- or IFN-γ-
stimulated SMC function is likely not attributed to cell death.
Rather, the observed changes in cell behavior are likely
attributed to the ability of DS-SILY20 to bind with high affinity
to both the ECM molecule collagen, and to the growth factors
PDGF and IFN-γ, thus effectively sequestering the growth
factors in the matrix and attenuating the impact of the growth
factors on SMC activity. Others have previously demonstrated
that PDGF binds to DS with an affinity ranging between 15 and
91 nM, depending on the source of the DS, and also to decorin
at an affinity of ∼16 nM.30,49 In the present work, the straight-
line correlation in the Scatchard-type plots shown for both
growth factors (Figure 1A,B, insets) suggests the presence of
the single type of PDGF or IFN-γ binding sites on DS-SILY20
with dissociation constants on the same order as those found
for DS and decorin. Consistent with the hypothesis that DS-
SILY20 is sequestering PDGF and IFN-γ, and thus, attenuating
its impact on SMCs, the relative ratios of phosphorylated
PDGF or IFN-γ receptors are decreased when PDGF- or IFN-
γ-stimulated SMCs are also treated with 10 μM DS-SILY20, as
compared to cultures stimulated with PDGF or IFN-γ alone
(Figure 2). While this is in contrast with work by Nili et al.
showing that PDGF is able to bind both decorin and its
receptor, the Nili et al. studies were performed using cell lysates
rather than in a format where decorin could bind to a collagen
matrix.19 In the present study, the DS-SILY20 is able to bind to
collagen surrounding the SMCs (Figure S4, Supporting
Information), supporting the idea that collagen-bound DS-
SILY20 sequesters the PDGF making it unavailable to bind to its
receptor.
SMC migration from the medial layer to the intimal layer,
accompanied by increase protein synthesis within the intimal
layer, is critical to intimal hyperplasia.50 Previously, we
demonstrated that proliferation, migration, and protein syn-
thesis were significantly increased in proliferative SMC
cultures.36 We further demonstrated that DS-SILY20 showed
no negative impact on quiescent cells, as evidenced by little to
no effect on protein synthesis, cell proliferation, or cell
migration. However, DS-SILY20 suppressed protein secretion,
cell migration, and cell proliferation in proliferative cultures.
Combined with the lack of effects on cell metabolism, this data
supports the notion that DS-SILY20 does not have deleterious
effects on normal cell behavior, but suppresses behavior that
leads to intimal thickening in proliferative SMCs.
In order to further evaluate the mechanism through which
DS-SILY20 suppressed intimal hyperplasia, we assessed the
effects of DS-SILY20 in PDGF stimulated morphological
changes, proliferation, and migration in SMCs exhibiting either
a proliferative or quiescent phenotype (Table 1; Figure 3).8,51
DS-SILY20 was able to overcome morphological changes
induced by PDGF in both proliferative and quiescent cultures
(Figure S3, Supporting Information). Consistent with other
studies, PDGF induced greater proliferation in quiescent cells
than in proliferative cells, perhaps because the proliferative cells
were already stimulated by factors present in the culture
medium.52 Similarly, PDGF demonstrated an increased potency
toward quiescent SMC migration. SMC migration has been
correlated with pERK-1/2 levels. Consistent with the increased
migration observed with PDGF stimulation in these studies, the
relative levels of pERK-1/2 in quiescent cultures exhibited a
larger fold increase compared to proliferative cultures (Figure
8).
Contrasting results were seen when stimulating with IFN-γ.
Similar to results observed with PDGF, IFN-γ stimulated
proliferation and migration in quiescent SMCs; however, it did
stimulate changes in cell morphology, which was negated by
treatment with DS-SILY20 (Figure S3, Supporting Informa-
tion). These confounding results between the two SMC
phenotypes demonstrate the complex nature of IFN-γ signaling
in tissue remodeling, adding to the conflicting reports depicting
IFN-γ as both pro- and antirestenotic.16,17,53 Interestingly, the
differential effects of IFN-γ have also been demonstrated
elsewhere, where IFN-γ addition to quiescent SMCs resulted in
increased proliferation and migration, while the growth factor
had either no effect or reduced proliferation and protein
synthesis in proliferative SMCs.8,12,53−56
The addition of DS-SILY20 to PDGF- or IFN-γ-stimulated
SMCs correlated to a dose-dependent inhibition of SMC
proliferation and migration in both SMC phenotypes,
demonstrating that DS-SILY20 retains bioactivity amidst the
presence of growth factors. It is likely that DS-SILY20 is able to
block SMC stimulation by sequestering PDGF or IFN-γ, thus,
limiting the stimuli’s ability to activate or further promote
restenotic SMC behavior in either injured and healthy SMC
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phenotypes. Interestingly, higher concentrations of DS-SILY20
were required to significantly reduce growth factor induced
migration in quiescent SMCs compared to proliferative
cultures. Increased concentrations of DS-SILY20 were also
required to mitigate increased relative levels of pERK-1/2 in
growth factor-stimulated quiescent cultures; however, further
investigation is needed to fully understand these findings.
Consistent with previous work and with the increased cell
proliferation and migration observed here, PDGF stimulated
protein synthesis in SMCs exhibiting either a proliferative or
quiescent phenotype (Table 1). Again demonstrating that
context is important in dictating whether IFN-γ is pro- or
antistenotic, IFN-γ stimulated protein synthesis in quiescent
SMCs, the growth factor reduced protein synthesis in
proliferative cultures. We speculate that the inconsistent results,
demonstrated previously in literature, associating IFN-γ as both
pro- and antirestenotic could be attributed to differences in cell
physiology, as determined by the SMC phenotype utilized. The
addition of DS-SILY20 to PDGF- or IFN-γ-stimulated SMCs
correlated to a dose-dependent inhibition of SMC protein
synthesis in both SMC phenotypes. As we observed overall
changes in protein synthesis, we hypothesized that we would
observe changes in JNK phosphorylation, which has been
correlated with collagen and fibronectin protein production.57
Surprisingly, phosphorylation of JNK did not change when
observed at 10 or 60 min post-treatment (data not shown).
However, it is possible that the static phosphorylation studies
did not capture the dynamic changes in JNK phosphorylation.
Since overall protein synthesis was increased in the
proliferative phenotype and via stimulation with PDGF, we
investigated whether ECM genes implicated in intimal
hyperplasia were also upregulated. Both collagen I and
fibronectin are upregulated in intimal hyperplasia, while
collagen III is often down-regulated.58,59 While PDGF has
been shown to stimulate collagen I, collagen III, and fibronectin
production in SMCs, the growth factor did not induce collagen
I, collagen III, or fibronectin gene expression in quiescent
cultures in this investigation (Figure 4).51,60,61 In this study,
PDGF stimulated quiescent SMC proliferation, which may shift
expression toward essential cellular proteins and away from
extracellular proteins. In fact, it has been demonstrated that the
vast majority of cells exhibiting proliferative activity are not
collagen-producing.62 This is in stark contrast with our results
demonstrating that in proliferative SMCs stimulated with
PDGF both an increase in proliferation and in collagen I and
fibronectin gene expression were observed; however, this too is
consistent with other studies.8,60 Furthermore, in the latter case,
increased type I collagen gene expression may also be attributed
to increased cytokine expression found in PDGF-stimulated
proliferative SMC cultures.63,64 These results clearly show that
environment and phenotypic state are critical factors in the
complex responses to cell stimulation.
Following vessel injury, active SMCs participate in the
inflammatory cycle by producing and secreting a range of pro-
inflammatory factors, in response to mechanical and chemical
stimuli.65 It has previously been established that SMCs dosed
with PDGF or IFN-γ exhibit an enhanced inflammatory
response, a phenomenon we further demonstrate in this
work.16,51 Consistent with studies demonstrating that DS-
SILY20 attenuates cytokine production in proliferative and
quiescent SMC cultures, we reveal here that DS-SILY20 reduces
the production of pro-inflammatory cytokines secreted from
PDGF- or IFN-γ-stimulated SMCs.36 As expected, the addition
of 10 μM DS-SILY20 to PDGF- or IFN-γ-stimulated cultures
decreased the production of all three inflammatory cytokines
investigated (Figures 5 and 6). Interestingly, the treatment of
cultures with PDGF or IFN-γ and low concentrations of DS-
SILY20 caused an increase of IL-1β and TNF-α. Consistent with
the increased IL-1β and TNF-α production observed, the
relative levels of pp38 also increased when stimulated with
PDGF or IFN-γ coupled with low DS-SILY20 concentrations
(Figure 9). This observed increase in IL-1β and TNF-α also
corresponds with sustained migration and pERK-1/2 levels
observed in quiescent SMCs under similar treatment
conditions, indicating that low concentrations of the compound
in the presence of chemical stimuli stimulates a small level of
smooth muscle cell repair and remodeling.66
In addition to the effect of DS-SILY20 on growth factor-
stimulated SMC cytokine production, the ability of this
antithrombotic therapeutic to influence cellular expression of
thrombomodulin is maintained in the presence of PDGF and
IFN-γ. Thrombomodulin, a transmembrane glycoprotein, plays
an important role in maintaining vascular thromboresistance as
it forms a complex with thrombin, allowing for the activation of
protein C and, thus, indirectly increasing fibrinolysis and
inhibiting blood coagulation.67 It has previously been
determined that the overexpression of thrombomodulin, or
similarly, the systemic administration of thrombomodulin,
reduces inflammatory cell infiltration and neointimal formation
in several animal models;68,69 thus, the ability to upregulate
thrombomodulin in proliferative, unhealthy SMCs may serve as
another important mechanism in the prevention of restenosis.
Thrombomodulin levels were significantly enhanced with the
introduction of PDGF or IFN-γ to proliferative SMC cultures,
attaining similar production levels to that of cultures treated
with 10 μM DS-SILY20 alone (Figure 7). However, the lack of
synergistic activity observed when proliferative cultures
received cotreatments of PDGF or IFN-γ and high concen-
trations of DS-SILY20 may be attributed to binding of PDGF
and IFN-γ to the mimic, limiting the influence of the growth
factors on cell behavior and as such that only the effects
associated with DS-SILY20 is observed. This claim is further
strengthened by the fact that treatment with low concentrations
of DS-SILY20 and PDGF or IFN-γ resulted in decreased
thrombomodulin production in proliferative cultures, similar to
previous results observed with DS-SILY20 alone.
19 However,
unlike in cultures treated with DS-SILY20 alone, thrombomo-
dulin production did not decrease below values observed in
controls, indicating that the combination of certain growth
factors with low concentrations of DS-SILY20 may be useful for
vessel remodeling and functional healing. Furthermore, while
the upregulation of thrombomodulin may prove important in
the treatment of proliferative, unhealthy SMCs, the ability to
maintain quiescent, healthy SMC behavior is also important.
Here, we demonstrate that the addition of PDGF or IFN-γ and
DS-SILY20 does not alter thrombomodulin production in
quiescent SMCs, demonstrating that the therapeutic admin-
istration maintains quiescent SMC health.
Decorin has been shown to affect pathways in addition to
PDGF and IFN-γ, perhaps most notably the TGFβ-1
pathway.70 With respect to TGFβ-1, binding to decorin has
been shown to be with the core protein rather than with the DS
chain. Thus, it is unlikely that the activities seen here are due to
altered TGFβ-1 signaling. While we have demonstrated
attenuation of PDGF and IFN-γ, it remains possible that DS-
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SILY20 binds to additional signaling molecules that also
contribute to the observed activity.
■ CONCLUSION
We previously demonstrated that the decorin mimic, DS-
SILY20 suppressed intimal hyperplasia following balloon
angioplasty at least in part through inhibition of platelet
binding to the lumen of the denuded vessel. To further
characterize the activity of DS-SILY20 proliferative and
quiescent cultures of SMCs were established, and the binding
affinities of DS-SILY20 with PDGF (32.2 ± 5.7 nM) and IFN-γ
(55.1 ± 6.9 nM) were established. The nanomolar dissociation
constants observed between DS-SILY20 and both PDGF and
IFN-γ, coupled with the ∼24 nM dissociation constant between
DS-SILY20 and collagen, suggest that DS-SILY20 is able to
attenuate the effects of these factors, released from activated
platelets, simply through sequestration. Consistent with this
hypothesis, DS-SILY attenuates the phosphorylation of the
PDGF and IFN-γ receptors in the presence of PDGF or IFN-γ,
respectively. In the case of PDGF, the growth factor
significantly increased migration, proliferation, and protein
and cytokine expression, as well as increased ERK-1/2 and p38
MAPK phosphorylation in both quiescent and proliferative
cultures. In all cases, DS-SILY20 inhibited these increases.
Consistent with the complex responses seen with IFN-γ in
SMC physiology in the literature, the response of SMC cultures
to IFN-γ was variable and complex. However, where increased
activity was seen with IFN-γ, DS-SILY20 attenuated this activity.
In no case did DS-SILY20 abolish cell function, suggesting that
while it is able to suppress intimal hyperplasia, it does not
interfere with normal cell behavior and, hence, will not suppress
healing associated with vessel injury. Furthermore, DS-SILY20
had a positive influence on thrombomodulin expression,
thereby making activated SMCs less thrombogenic. Overall,
the results suggest that DS-SILY20 would be an ideal alternative
to traditional therapeutics used following PCI. The results
warrant further characterization of DS-SILY20 with endothelial
cells to evaluate the ability of endothelial cell regrowth. This
regrowth is inhibited by sirolimus and paclitaxel, which are
commonly used to inhibit intimal hyperplasia following PCI;
the lack of regrowth can lead to long-term issues including the
need to systemically anticoagulate patients and the inability of
the body to reestablish critical cell signaling between
endothelial cells and smooth muscle cells.
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